# Evaluation of the Efficacy and Safety Observation of IBI311 Treatment in Patients With Inactive TAO

> **NCT07152392** · PHASE4 · RECRUITING · sponsor: **Shanghai Changzheng Hospital** · enrollment: 50 (estimated)

## Conditions studied

- Thyroid Associated Ophthalmopathies

## Interventions

- **DRUG:** IBI311
- **OTHER:** Follew-up

## Key facts

- **NCT ID:** NCT07152392
- **Lead sponsor:** Shanghai Changzheng Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-04-15
- **Primary completion:** 2027-07-01
- **Final completion:** 2035-04-15
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2025-09-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07152392

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07152392, "Evaluation of the Efficacy and Safety Observation of IBI311 Treatment in Patients With Inactive TAO". Retrieved via AI Analytics 2026-06-29 from https://api.ai-analytics.org/clinical/NCT07152392. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*